Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Viking Therapeutics, Inc. (VKTX) closed at $28.19 in the latest trading session, marking a +1.7% move from the prior day.

There are many promising corporations that investors can buy on a dip due to recent market volatility or company-specific ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $26.52, representing a -5.86% change from its previous close.

Truist Financial analyst Joon Lee maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) today. The company’s shares closed yesterday at $27.09. Confident Inv ...

Shares in biopharmaceutical company Viking Therapeutics (NASDAQ: VKTX) were up by 6.3% at 12:30 a.m. ET today. The move ...

Viking begins phase III VANQUISH program for VK2735, targeting weight loss in obese adults with or without type II diabetes.

Currently, the analyst consensus on Viking Therapeutics is a Strong Buy with an average price target of $90.69, which is a 234.53% upside from current levels. In a report released today, BTIG also ...

Viking Therapeutics begins Phase 3 trials for VK2735, testing weekly injections in over 5,000 adults with obesity or type 2 diabetes over 78 weeks.